Related Experiment Videos
p53 and RAS gene mutations in multiple myeloma.
M Portier1, J P Molès, G R Mazars
1INSERM U291, Immunopathologie des Maladies Tumorales et Autoimmunes, Montpellier, France.
Oncogene
|December 1, 1992
Summary
Activating mutations in RAS genes are more common than p53 gene mutations in multiple myeloma (MM). Both RAS and p53 alterations are linked to advanced stages of this blood cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Multiple myeloma (MM) is a cancer of plasma cells.
- Understanding genetic alterations in MM is crucial for prognosis and treatment.
Purpose of the Study:
- To investigate the frequency and types of mutations in the p53 and RAS genes in multiple myeloma patients.
- To correlate these genetic alterations with disease phase and aggressiveness.
Main Methods:
- Genomic DNA analysis from 30 MM patients and 10 MM cell lines.
- Polymerase chain reaction (PCR) and single-strand conformation polymorphism (SSCP) techniques were employed.
- Specific analysis focused on exons 5 and 7 of the p53 gene and codons 12, 13, and 61 of RAS genes (K-RAS, N-RAS, H-RAS).
Main Results:
- p53 gene mutations were found in 20% of patients, primarily G:C to A:T transitions in conserved regions, and were associated with the terminal disease phase.
- RAS gene mutations occurred in 47% of patients, affecting K-RAS or N-RAS at codons 12, 13, or 61. One patient had simultaneous K-RAS and N-RAS mutations.
- RAS mutations were more prevalent in fulminating disease (67%) compared to less aggressive forms (26%).
- Analysis of myeloma cell lines revealed mutations in K-RAS and N-RAS.
Conclusions:
- Activating RAS gene mutations are more frequent than p53 mutations in multiple myeloma.
- Both p53 and RAS gene mutations appear to be associated with the terminal phases of multiple myeloma.
- These findings highlight the role of RAS and p53 alterations in MM progression.